February 11, 2026

Fetal Spina Bifida Surgery Advances: Fewer Risks, Better Outcomes

At the Fetal Care Center, WashU Medicine surgeons perform both open and fetoscopic myelomeningocele repair, offering families results that exceed benchmarks

Barnes-Jewish

February 09, 2026

Managing Idiopathic Acute Pancreatitis

Expert panel weighs evidence for genetic testing, cholecystectomy, and ERCP in patients with unexplained acute pancreatitis amid limited guideline direction.

Conexiant

January 29, 2026

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Two genetic subtypes of childhood B-cell acute lymphoblastic leukemia (B-ALL) have long been associated with inferior treatment outcomes: Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL.

Roswell Park Comprehensive Cancer Center

January 26, 2026

Myopia: Evidence That Endures

Why robust long-term clinical myopia control evidence is crucial for protecting children’s vision

The Ophthalmologist

January 09, 2026

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

The FDA's approval of recombinant ADAMTS13 marks a significant advancement in managing congenital thrombotic thrombocytopenic purpura, ensuring better care for patients suffering from this rare condition.

JADPRO

December 25, 2025

Lasting Retinal Effects in Preterm Babies

The long shadow of prematurity: what adult retinas reveal decades later

The Ophthalmologist

December 23, 2025

Rare Disease Reanalysis Ended Our 5-Year Wait

In conversation with the clinician who developed the proactive exome reanalysis approach, and the mother whose child benefited from it

The Pathologist

December 22, 2025

Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities

A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden on...

The ASCO Post

December 17, 2025

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

Dana-Farber